Oxcarbazepine is a new anticonvulsant with an active metabolite. It is approved as mono- or adjunctive therapy for partial seizures in adults and children older than 4 years of age and as adjunctive therapy in children 2 years and older. Its spectrum of anticonvulsant activity is comparable to carbamazepine, but it has an improved pharmacokinetic profile, is better tolerated and is associated with few clinically significant drug-drug interactions.

This content is only available as a PDF.